Skip to main content

Vericel Corp

VCEL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000887359

In the last 90 days, Vericel Corp insiders filed 0 open-market purchases and 3 sales; 320 institutions reported holding it in 13F filings for Q2 2026, worth $2.47B in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Vericel Corp changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of VCEL: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders2142227+15
Shares51.4M7.05K51.8M+459.0K (+0.9%)
Value$1.73B$236.1K$1.84B+$120.0M (+7.0%)

2 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (30)

Institutions that held Vericel Corp at the end of Q4 2023 but not at the end of Q3 2023.

Sold out (15)

Institutions that held Vericel Corp at the end of Q3 2023 and filed for Q4 2023 without it.

Not filed for Q4 2023 yet (2)

Institutions that held Vericel Corp at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VCEL in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
First Republic Investment Management, Inc.7,014$235.1K
Steward Financial Group LLC39$1.00K